Skip to main content
GIPResearch.com · Patent and Technology Research

AbbVie Germany GmbH & Co. KG. Receives a Patent for Polymeric Carrier Composition

AbbVie Germany GmbH & Co. KG. is a global, research-based BioPharma company focused on researching and developing innovative therapies for some of the world's most serious and complex diseases. In India, the Pharmaceutical business of AbbVie Germany GmbH & Co. KG. is focused on Modulators of 5-HT…

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for AbbVie Germany GmbH & Co. KG. Receives a Patent for Polymeric Carrier Composition
Research and original publication material

AbbVie Germany GmbH & Co. KG. Receives a Patent for Polymeric Carrier Composition — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

AbbVie Germany GmbH & Co. KG. is a global, research-based BioPharma company focused on researching and developing innovative therapies for some of the world's most serious and complex diseases. In India, the Pharmaceutical business of AbbVie Germany GmbH & Co. KG. is focused on Modulators of 5-HT Receptors, Anti-EGFR Antibody Drug Conjugate (ADC), Carbamate-Substituted Oxindole Derivatives, Amidomethyl-Substituted Xindole Derivatives, Anti-A? Globulomer Antibodies. AbbVie Germany GmbH & Co. KG. filed patent application numbered 8568/CHENP/2010 that is titled as PHARMACEUTICAL DOSAGE FORM COMPRISING POLYMERIC CARRIER COMPOSITION. This patent application has been granted as Patent Number 297310. The invention covers the field of pharmaceuticals. This invention relates to pharmaceutical dosage from comprising a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the claims 1-10 are non- patentable because no enhancement in efficacy (or synergistic effect) has been indicated. Hence these claims fall within the scope of Section 3(d) of the Indian Patent Act. As a response to said objection, the applicant responded by submitting technical and legal arguments by stating the differentiating on the basis of thermal and mechanical properties to bring the novelty factor. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to AbbVie Germany GmbH & Co. KG. Receives

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-08-07. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights